Form 4: REVB CFO Sells Shares for Tax Obligations

Revelation Biosciences CFO Chester Zygmont III sold 13,100 shares of common stock to cover tax withholding obligations following a restricted stock award vesting.

Summary

• Chester Stanley Zygmont III, Chief Financial Officer of Revelation Biosciences, Inc. (REVB), reported the disposition of common stock.
• On February 4, 2026, 13,100 shares of common stock were sold.
• The sale was mandatory and solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards.
• The shares were sold at a weighted average price of $1.65, with individual transaction prices ranging from $1.63 to $1.66.
• All share numbers reported reflect a 1-for-4 reverse stock split that became effective on January 28, 2026.
• Following this transaction, Mr. Zygmont beneficially owns 105,348 shares directly, 2 shares indirectly through The Zygmont Family Trust, and 2 shares indirectly through Czeslaw Capital Fund, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was mandatory for tax purposes and not a discretionary investment decision, though the reverse stock split context adds a layer of consideration regarding the company's stock structure.

Positives

• The transaction indicates the vesting of restricted stock awards, representing compensation for the Chief Financial Officer.

Negatives

• The sale of 13,100 shares by a key executive, even for tax purposes, results in a reduction of their direct equity stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that mandatory tax-related sales by executives are common occurrences following the vesting of equity awards and are generally not indicative of a change in management's confidence in the company's future. The mention of a 1-for-4 reverse stock split effective January 28, 2026, however, could be a signal of efforts to maintain listing compliance or improve share price perception, a strategy often seen in smaller biotechnology firms.

Related Party Transactions

• Indirect beneficial ownership of 2 shares is held by The Zygmont Family Trust Dated October 25, 2016, with Chester S Zygmont III serving as a trustee.
• Indirect beneficial ownership of 2 shares is held by Czeslaw Capital Fund, LLC, with Chester S Zygmont III as the sole manager.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in the CFO's direct equity stake, but as a mandatory tax-related transaction, it typically has minimal impact on shareholder sentiment. The previously announced 1-for-4 reverse stock split impacts the number of shares outstanding and the per-share price.
• Employees: The vesting of restricted stock awards is a positive for the CFO as an employee, representing a realized component of their compensation package.

Key Dates

Recommendation

The transaction is a mandatory sale for tax withholding purposes following the vesting of restricted stock awards, which is a routine event and does not reflect a discretionary investment decision by the CFO. While the reverse stock split might raise questions about the company's stock performance or strategy, this specific Form 4 filing itself provides no new fundamental information to alter an existing investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

REVELATION BIOSCIENCES, REVB, Form 4, insider transaction, CFO, stock sale, tax withholding, restricted stock, reverse stock split